Table 1.

Clinical trials in spinocerebellar ataxia type 2 patients.

Treatment	Doses	Type of trial	n	Follow-up (months)	Outcome
Lithium carbonate (116)	Starting with 150 mg BID until total daily dose of 1,500 mg or serum level of lithium (0.9–1.2 mEq/L)	Double blind, placebo	16	12	Non-significant changes in SARA and brain volume. Significant reduction in the BDI
Riluzole (117)	100 mg daily	Double blind, placebo	16	12	Decrease of SARA score
Zinc sulfate (112)	50 mg daily	Double blind, placebo	36	6	Improved gait, posture, stance, dysdiadochocinesia, and reduction of saccadic latency
Lisuride (118)	0.1 mg daily 1 h before bedtime	Open label	12	1	Decrease in PLMS index and improved subjective sleep quality
B vitamins (119, 120)	10,000 U/weeks during first 4 weeks and 5,000 U/weeks until 12th week	Open label	20	3	Improved sensory neuropathy and painful muscle cramps

SARA, Scale for Assessment and Rating of Ataxia; BDI, Beck’s depression inventory; PLMS, periodic leg movement syndrome.